Nurix: Two sides of protein degradation

How Nurix is tackling protein degradation by inhibiting or harnessing E3 ligases

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a protein’s levels. The latter is the basis of its preclinical immuno-oncology partnership with Celgene Corp.

Backed by a $25.1 million series B from Third Rock Ventures and The Column Group and funds from Celgene, Nurix Therapeutics Inc. has developed two platforms

Read the full 757 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE